Rivoglitazone

DB09200InvestigationalSmall molecule

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma
Curator reviewed
Formula / weight: C₂₀H₁₉N₃O₄S · 397.45 g/mol (avg)
Code names: CS-011

Resolves to

Compound

UNII3A3N0634Q6CAS185428-18-6ChEMBLCHEMBL2104753PubChem3055168

Structure

InChIKeyXMSXOLDPMGMWTH-UHFFFAOYSA-NSMILESCOC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1

Targets

P37231PPARG

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

837Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rivoglitazone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account